Beranda › Neurofibrosarkoma › New York
Uji klinis Neurofibrosarkoma di New York
6 studi untuk Neurofibrosarkoma mencari peserta di lokasi di New York.
Kota di New York
Teks studi resmi (Bahasa Inggris)
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- New York University Langone Health, New York
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05732831Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Perlmutter Cancer Center at NYU Langone Hospital Long Island, Mineola
- David H Koch, Memorial Sloan Kettering Cancer Center, New York
- New york cancer and blood specialists - Oncology, Port Jefferson Station
- dan 1 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05245500SPEARHEAD-3 Pediatric Study
- Memorial Sloan Kettering Kids, New York
Menerima pesertaFase 1/2
Usia 2 hingga 21 · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05642455A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
- dan 1 lainnya
Menerima pesertaFase 2
12 Months · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT05985161Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
- Memorial Sloan Kettering Cancer Center, New York
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 9 Mar 2026 · NCT03141021A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
- Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center, New York
- dan 1 lainnya
Menerima pesertaFase 2
Usia 16 ke atas · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT04872543Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.